Immuto Scientific has entered into a research collaboration with an unnamed, U.S.-based multinational animal health company, the company announced today.

According to a release, the collaboration is designed to apply Immuto’s structural proteomics platform to identify novel targets involved in chronic inflammatory dermatologic conditions in companion animals.

“This partnership expands the application of Immuto’s structural surfaceomics platform into new therapeutic areas,” Immuto Scientific Co-Founder and CEO Faraz A. Choudhury, PhD, said in a statement. “We are pleased to collaborate with an industry leader to explore how these insights can support new approaches in both animal and human health.”

Both organizations will contribute scientific and technical resources to a structured research plan focused on analyzing healthy and disease models.

Financial terms were not disclosed.